+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Diabetic Retinopathy - Epidemiology Forecast to 2032 - Product Thumbnail Image

Diabetic Retinopathy - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Hypoparathyroidism - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hypoparathyroidism - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Somatotropin - Biosimilar Insight, 2022 - Product Thumbnail Image

Somatotropin - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 70 Pages
  • Global
From
Insulin Glargine- - Biosimilar Insight, 2022 - Product Thumbnail Image

Insulin Glargine- - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Acromegaly - Epidemiology Forecast to 2032 - Product Thumbnail Image

Acromegaly - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
22q11.2 Deletion Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

22q11.2 Deletion Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Congenital Hyperinsulinism - Epidemiology Forecast to 2032 - Product Thumbnail Image

Congenital Hyperinsulinism - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Axillary Hyperhidrosis - Epidemiology Insight - 2032 - Product Thumbnail Image

Axillary Hyperhidrosis - Epidemiology Insight - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Farber's disease - Epidemiology Insight - 2032 - Product Thumbnail Image

Farber's disease - Epidemiology Insight - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
VENGLUSTAT - Emerging Insight and Market Forecast - 2030 - Product Thumbnail Image

VENGLUSTAT - Emerging Insight and Market Forecast - 2030

  • Report
  • February 2021
  • 50 Pages
  • Global
From
ARIMOCLOMOL - Emerging Insight and Market Forecast - 2030 - Product Thumbnail Image

ARIMOCLOMOL - Emerging Insight and Market Forecast - 2030

  • Report
  • February 2021
  • 50 Pages
  • Global
From
From
Elagolix - Launch Insight, 2019 - Product Thumbnail Image

Elagolix - Launch Insight, 2019

  • Report
  • January 2019
  • 50 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more